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Abstract
A novel linear-dendritic block copolymer has been synthesized and evaluated for targeted
delivery. The use of the dendron as the micellar exterior block in this architecture allows the
presentation of a relatively small quantity of ligands in clusters for enhanced targeting, thus
maintaining a long circulation time of these “patchy” micelles. The polypeptide linear
hydrophobic block drives formation of micelles that carry core-loaded drugs, and their unique
design gives them an extremely high level of stability in vivo. We have found that these systems
lead to extended time periods of increased accumulation in the tumor (up to 5 days) compared to
non-targeted vehicles. We also demonstrate a 4x increase in efficacy of paclitaxel when delivered
in the targeted nanoparticle systems, while significantly decreasing in vivo toxicity of the
chemotherapy treatment.
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Background
Amphiphilic polymers can be designed to function as physical drug carriers in the form of
micelles(1,4), permitting the entrapped drug to benefit from the enhanced material properties
of the polymer nanocarrier. However, several problems still exist with micellar delivery
systems. In typical carrier designs, where an anti-fouling polymer such as poly(ethylene
glycol) forms the surface of the carrier, the addition of targeting ligands on the same surface
nullifies the anti-fouling properties of the carrier(5-8), resulting in decreased circulation
times; because of this, a key challenge to drug delivery is in the balancing of these
parameters to impart the most favorable of both properties. While clinical trials of micellar
delivery systems have demonstrated improved pharmacokinetics and a greater tolerance
with patients, dose-limiting toxicities attributed to the drug still occurs at higher dosage
levels(9-11), suggesting that on some level, the encapsulated drug dissociates from the
carrier in vivo. In studies to evaluate the stability of core-loaded drugs in vivo, it was found
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that certain in vivo conditions promote the rapid release of encapsulated drugs(12), which
can happen within an hour after systemic administration.
To optimize both circulation and targeting, we propose that ligand clustering, which has
been shown to modulate cell adhesion and mobility on planar surfaces, can also be used as a
strategy to increase tumor targeting afforded by available ligands(13,14). Through rational
design, we use a block copolymer capable of highly controlled surface ligand presentation
and drug loading capability by combining aspects of (i) amphiphilic linear block
copolymers(15), which have the advantage of being able to entrap and protect drug in the
nanocarrier core via self assembly(16), and (ii) dendrimers(17) which present polyvalent
terminal units to concentrate ligands for multivalent clustered binding. This capability is
particularly key to the generation of the highest affinity nanoparticle surfaces and increased
specificity of intracellular uptake. The linear dendritic polymer(18) (LDP) is amphiphilic in
nature, with a hydrophobic linear block independently designed to entrap drug and a
hydrophilic dendritic block. An added benefit of the linear-dendritic architecture is the
formation of extremely stable micelles as a result of a more effective packing of the cone-
like linear-dendritic amphiphiles(18), leading to extremely low critical micelle
concentrations (CMC) of order 10-8 mol/l, which allows the carrier to be resistant to
destabilization in vivo. Formation of mixed micelles with non-functional dendritic blocks
allows self-assembly into “patchy” ligand-clustered micelles for encapsulation of
hydrophobic drugs.
Folate(19,20) has been explored in great detail for targeted cancer delivery because of the
overexpression of FRs on many cancer cell types(21), particularly ovarian cancer, allowing
a means for tumor selective delivery of cytotoxic drugs. In separate work, we have shown
that the use of ligand-clustered micelles for folate targeting of ovarian tumor cells yields
enhanced uptake both in vitro and in vivo, and that an optimum exists for cluster size and
density on the patchy micellar surface ((Poon et al, Angewandte Chemie, 2010)). Herein, we
investigate the use of these optimized novel self-assembled constructs, capable of presenting
ligand in predetermined clusters on nanoparticle surfaces for cell targeting, as a means of
selectively targeting drug-loaded nanocarriers for chemotherapeutics. We prepared
paclitaxel PTX(22,23) encapsulated LDP “patchy” micelles that present folate in clusters
and investigated the efficacy of the optimized patchy micellar system in tumor targeting, its
viability as a stable drug carrier in serum and in vivo, as well as its efficacy for intravenous
delivery of chemotherapeutics with low bioavailability.
Experimental Section
Materials
All chemicals and biologicals were purchased from Sigma-Aldrich unless otherwise noted.
Paclitaxel (PTX) was purchased from LC laboratories. BALB/c mice were from Charles
River, nude mice were purchased from Taconic and the folate free diet from Research Diets.
All mice were fed a folate free diet for at least a week before experimentation to attain blood
folate levels that are similar with humans. All in vivo experimentation was carried out under
the supervision of the Division of Comparative Medicine (DCM), Massachusetts Institute of
Technology, and in compliance with the Principles of Laboratory Animal Care of the
National Institutes of Health. Cell lines were purchased from ATCC and were tested
routinely for pathogens before use in animals via DCM.
Synthesis of PBLA-Polyester-PEG Linear Dendritic Polymer (LDP) and folate conjugation
The linear dendritic polymer was synthesized according to published protocols(18) with β-
benzyl-L-aspartate replacing n-dodecyl-L-glutamate as the hydrophobic linear block. Folic
acid was also conjugated via DCC/NHS chemistries. (Xn = 12-15). 1H NMR (CDCl3): δ1.12
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(m, 24H, -CH3), δ1.25 (m, 21H, -CH3), δ2.67-3.06 (bs, -COCH2), 3.60 (d, 16H, -CH2O),
δ4.13 (d, 16H, -CH2O), δ4.24-4.32 (m, 28H, -CH2O), δ4.56 (m, -CHNH), δ5.03 (bs, -
CH2Ar), δ7.22 (bs, -ArH). The steps for labeling of the polymer with radioisotopes and
fluorescent dyes can be found in the supplemental information section.
Preparation of PTX loaded micelles
PTX was entrapped within both folate targeted and non-targeted LDP micelles using a nano-
precipitation method. The folate presenting micelle was self-assembled in a ratio of
2(unfunctionalized LDP): 3(20% folate functionalized LDP). A weight ratio of 10:0.25 LDP
to PTX was concentrated in DMSO and mixed dropwise into PBS (at least 20X the volume
of DMSO). The resultant micelles were dialyzed in a 3KMWCO dialysis bag against a PBS
sink for 4h to remove the trace amount of DMSO and filtered with a 0.45 μm teflon syringe
filter before use. Additional characterization information is located in supplemental
information.
Confocal analysis
KB cells overexpressing the FR receptor were cultured in FA free media on chamber slides
for at least 4 days before use. PTX-AF488 conjugate (Invitrogen) was encapsulated in
targeted and untargeted micelles labeled with AF647 described above. After incubation,
cells were washed with PBS (2% BSA), fixed, permeabilized and stained with Hoechst
before analysis with a Deltavision confocal.
In vivo experimentation
For biodistribution, a single dose of 111In-labeled micelles (untargeted and folate targeted,
10 mg/Kg) was given via the tail vein to nude mice induced with a KB xenograft (106 cells/
subcutaneous injection. At predetermined time points, the mice were sacrificed and their
tumors, liver, kidney, spleen, heart, lungs and blood were harvested, weighed, solubilized
and radio-counted on a Beckman LS6000 scintillation counter. Animals were euthanized
with CO2 followed by cervical dislocation to confirm death. Quantitative measurements of
accumulation in different tissues were normalized by the total injected dose and reported as
percentage injected dose per gram tissue (%ID/g).
Toxicity of treatment was assessed in BALB/c mice (~6 months old, Charles River) given
biweekly injections of various PTX containing treatments. The weight of the mice was
measured regularly as an indicator of acute toxicity and blood serum was collected 4 days
after the conclusion of the experiment for analysis of toxicity markers. Anti-tumor efficacy
was evaluated in nude mice (3-4 weeks old, Taconic) induced with KB tumors on a single
flank. Mice were randomized when the tumors were palpable (day 4) and given 4 biweekly
doses of treatment ((i) untargeted LDP micelles (100 mg/kg) delivering 2.5 mg/kg PX, (ii)
folate targeted LDP “patchy” micelles (100 mg/kg) delivering 2.5 mg/kg PTX, (iii) 2.5 mg/
kg free PTX in 1:1 Cremophor:EtOH (1 %v/v) as excipient, (iv) 10mg/kg free PTX in 1:1
Cremophor:EtOH (1%v/v) as excipient (v) LDP micelles (100 mg/kg) without PTX and (vi)
Saline) on days 4, 8, 12 and 16. Throughout the trial, their weights and tumor sizes were
measured once in 4 days. The length and width of the tumors were measured with calipers
and the volume of the tumor was determined with the following equation: (width2 X length)/
2. Tumors that were just palpable were assigned a volume of 1 mm3. The mice were
monitored for up to 60 days or until one of the following end points for euthanasia was met:
1) the body weight of the mice dropped below 15% of its initial weight, 2) the tumor burden
was >2.0 cm across in any dimension, 3) the mouse became lethargic, sick or unable to feed
or 4) the mouse was found dead. At the conclusion of the trial (day 60), all mice were
euthanized. One-way ANOVA tests at the 95% confidence interval were used for
comparison of tumor sizes.
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For histology, tumors were harvested from a separate group of mice receiving the same
treatment, frozen in OCT (-80 °C) and cut into 5 μm sections for analysis. Sections were
fixed (5% formaldehyde) and permeabilized with cold ethanol (70% volume). TUNEL assay
was performed according to the manufacturer’s instructions (Molecular Probes), CD31-
FITC conjugate was used to stain blood vessels and the nuclei were stained with Hoechst.
Sections were examined with a Delta Vision confocal at 20X.
Results
Preparation and characterization of PTX loaded LDP micelles
The LDP has a fully biodegradable chemical composition (Figure 1A); the hydrophobic
linear polypeptide block (poly(β-benzyl-L-aspartate)) forming the micelle core degrades into
natural amino acids in the presence of acid and enzymes in the endosome/lysosome and the
hydrophilic polyester-PEG block degrades into low molecular weight products that are
readily absorbed and eliminated by the body. The apparent molecular weight was
determined to be ~ 15,000 Da (polyester-PEG dendron ~ 12,000 Da; linear poly(β-benzyl-L-
aspartate) ~ 3000 Da). Full synthetic details are reported separately(18). PTX was loaded in
the polymeric micelles non-covalently via self-assembly of amphiphilic LDPs in aqueous
milieu. During assembly, hydrophobic PTX is entrapped within the micelle core and the
polyester-PEG dendron forms a dense anti-fouling shell around the micelle. Generation of
the polymeric micelles was confirmed by AFM (Figure 1B). The anti-fouling shell of
densely packed short PEG chains reduces non-specific uptake by non-targeted cells and
prevents premature clearance of the micelles by the reticuloendothelial system (RES)(1, 3,
24). Folate-targeted micelles optimized for circulation and targeting were prepared using a
mixed ratio of LDP and LDP pre-functionalized with folate on the dendron; this resulted in
the formation of “patchy” micelles, on which folate is presented in clustered groupings of
~3-4 on approximately half of the micelle surface. Folate thus occupies approximately 10%
of the surface (~4-5 wt% of micelle), leaving the other 90% exposed as poly(ethylene
glycol).
The PTX loaded micelles have a hydrodynamic diameter of 80±6 nm (mean±SD, n=10)
with polydispersity of ~ 1.2 and a negative surface charge of -25±3 mV (mean±SD, n=10).
Addition of folate increased the hydrodynamic diameter by ~10 nm and the surface charge
by ~ +5 mV. The micelles have a low critical micelle concentration (CMC) of ~10-8 M. PTX
can be loaded into the micellar systems with drug loading weight efficiencies up to 40 wt%,
leading up to ~2 orders of magnitude increased effective solubility of PTX, but PTX-loaded
micelles with 1-5 wt% PTX were found to be most stable ex vivo (Figure 1C). At low
loadings, PTX is stable within the micelle core; drug release for 2.5 wt% PTX loaded
micelles in serum at 37 °C and pH 7.4 were 12±2% and 15±6% at 24 h and 48 h respectively
(mean±SD, n=3). Upon exposure to a lower pH of 5.5, PTX release from micelles is greatly
enhanced (12 h: 40±6 % and 48h: 68±10 %, mean±SD, n=3), indicating that a lower pH in
the endosome provides a means for block copolymer breakdown, resultant micelle
destabilization and drug release.
Pharmacokinetics and stability of PTX-loaded LDP micelles
Post intravenous injection in mice (n=3-5), blood plasma concentrations of the micelle
carrier, encapsulated PTX (2.5 wt%) and free PTX (2.5 wt% equivalent) decreased in a two-
phase log-linear fashion shown in Figure 2A and 2B. Their calculated pharmacokinetic
parameters are given in Figure 2C (two compartment model(25)). The mean±SEM
distribution half lives (t½, distribution) of the LDP micelles, encapsulated PTX and free PTX
were 1.83±0.3 h, 1.72±0.2 h, and 0.61±0.4 h and their elimination half lives (t½, elimination)
were 15.63±2 h, 9.06±2 h, and 4.32±3 h respectively. The similar t½,distribution but different
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t½,elimination values for the LDP micelles and encapsulated PTX suggests that while
encapsulated PTX was distributed within the micelle carrier for the first few hours after
injection, the entrapped PTX gradually leaks out of the micelle and is cleared from the body
separately as free drug. While the micelles are in systemic circulation, we believe that the
main mechanism for loss of PTX is a gradual diffusion process from the micelle core, and
PTX loss via micelle destabilization is kept to a minimum. Ex vivo experimental
observations support this hypothesis, and show that the half-life for micelle destabilization
in serum is approximately 50 h, which is much greater than the half-lives of elimination of
the micelle from the body (Supplemental Figure 1). The mean±SEM for the rates of
distribution and elimination are Kdistribution = 0.38±0.08 h-1 for micelles and 0.40±0.07 h-1
for encapsulated PTX; Kelimination = 0.04±0.02 h-1 for micelle and 0.08±0.04 h-1 for
encapsulated drug. As a small molecule drug, free PTX was distributed and cleared at a
much higher rate (14x increase) compared to encapsulated PTX (mean±SEM: Kdistribution =
1.13±0.3 h-1, mean Kelimination = 0.16±0.2 h-1), owing to a higher degree of extravasation
into tissue and renal clearance(2); therefore, the calculated AUC value for encapsulated PTX
is also higher than free PTX, indicating a much higher bioavailability of the drug if
administered within the LDP micelles.
Biodistribution of micelles
The time dependent biodistribution and elimination of the LDP micelles as well as the
ability of folate-functionalized micelles to target folate receptor (FR) positive KB(28,29)
xenograft tumors were tested in nude mice (n = 3-5 per group, single flank tumor ~ 500
mm3). This data is shown in the form of plots of the percentage of injected dose
accumulated in different organs over a period of 5 days (Figure 3A and 3B). Compared to
non-tumored mice (mean±SEM: 37±3 %ID/g at 2.5 h), blood concentration of the micelles
decreased at a higher rate (3X) in tumored mice; within 3 h, micelle concentration decreased
to 12±4 %ID/g and 9±3 %ID/g (mean±SEM) tissue for non-targeted and targeted micelles
respectively. The faster decrease in micelle concentration in the blood is attributed to the
presence of the KB tumor, which increases the rate of micelle accumulation in the tumor
interstitials due to EPR. Vessel rich organs were found to contain significant levels of the
micelles within 5 min after injection, and this trend is typical of a two-phase distribution and
elimination pharmacokinetics. Aside from the tumors, micelle levels in all organs gradually
decreased over a period of 3-5 days after injection. By day 5, most of the injected micelles
were cleared from the body. The clearance patterns of micelles from the heart and lungs
were similar, and no significant accumulation of micelles was observed in these vital organs.
In contrast, we observed higher levels of the micelle in both the kidney and liver until day 3,
indicating that urinary excretion and phagocytosis by the reticuloendothelial system (RES)
are mechanisms for clearance of polymeric micelles. Most organs are also not known to
express FRs(21) and therefore do not show any differences between the targeted and non-
targeted micelles; however, FRs are expressed in both the kidney and liver, contributing to
the accumulation of a generally higher %ID/g level of folate-targeted micelles compared to
the untargeted micelles in these organs. The expression of FR in the kidneys is limited to the
apical membrane of proximal tubule cells, and thus they would only bind to folate filtered
past the glomerulus(30,31); therefore, the higher %ID/g levels in kidneys for the targeted
formulation is very likely due to the retention of filtered micelles (or partially hydrolyzed
LDP) via FR in the proximal tubule rather than drug containing micelles. By day 1, when
most of the injected micelles were already cleared from the blood, accumulation in the
kidney was 16±2 %ID/g for the folate-targeted micelles and 10±3 %ID/g for the untargeted
micelles (mean±SEM).
Only the targeted micelles continuously accumulate in the tumors over a 5 day period, with
the levels actually increasing for a few days before eventually decreasing (mean±SEM
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increased from 5±0.4 %ID/g at 5min to 10±2 %ID/g at day 3) during a period of time when
most of the non-targeted micelles were already cleared from the blood stream, a clear
indicator that specific receptor mediated uptake and retention of targeted micelles was
occurring. In contrast, EPR targeting of non-targeted micelles was only able to sustain high
%ID/g levels for ~ 1 day; %ID/g levels in the tumor dropped from 5±0.5 %ID/g to 1±0.3
%ID/g between days 1 and 3. These observations are in agreement with a previous study
that demonstrated longer and stronger retention of optimally targeted micelles in tumors 48
h after their administration (Poon et al, Angewandte Chemie, 2010). In addition to a high
degree of retention, the targeted micelles were also able to extravasate within the tumor
tissue (Figure 3C). We believe that the size of the LDP micelles (~80 nm in diameter) allows
easy penetration of tumor tissue so that efficacy of treatment will not be hampered by
inefficient delivery of chemotherapeutic agents.
Toxicity of the LDP micelles
Mice (3-5 per group) were given biweekly injections of the following: 1) LDP micelles (10
mg/kg) encapsulating PTX (2.5 wt%), 2) LDP micelles (10 mg/kg), 3) free PTX (2.5 wt%
encapsulated equivalent) with 1:1 Cremophor:EtOH (1 %v/v) as excipient, 4)
Cremophor:EtOH (1 %v/v) in PBS and 5) Saline for a total of 8 doses. The equivalent dose
of PTX given for all injections containing PTX was 2.5 mg/kg. While no deaths occurred
during the month long study, mice receiving free PTX injections lost between 10-12% of
their original weight (Supplemental Figure 2) and began to show signs of hair loss after 6
injections (data not shown). Mice receiving LDP micelles with and without encapsulated
PTX showed no signs of toxicity. Using an unpaired student’s t-test, statistical analysis of
their body weights on day 30 showed that mice receiving free PTX had statistically lower
body weights (0.0064 < P value < 0.0157, 95% confidence interval) than those in treatment
groups 1), 2), 4) and 5). A liver panel analysis of serum collected 4 days after the conclusion
of the study showed generally elevated levels of biomarkers for toxicity in mice that were
receiving free PTX doses (Table 1). Similar unpaired t-tests conducted for LDP + PTX and
PTX groups showed that the levels of ALK, ALT and AST (P = 0.0013, 0.0029 and 0.0353
respectively), as well as the weights of the spleen (P = 0.0156, 95% confidence interval)
were statistically different.
PTX uptake and cellular trafficking
Confocal analysis of cells after 5 h of incubation with targeted micelles shows a strong
overlay signal of both LDP micelle and PTX fluorescence within cytoplasmic compartments
(Figure 4), indicating that the PTX-micelle conjugates are internalized (FR mediated) into
endosomal compartments as whole micelles, where they can remain as a stable complex for
up to 5 h. After 10 h, neither PTX nor micelle fluorescence were observed in punctuate
structures within the cell; instead, diffused PTX and micelle fluorescence were found within
the cytosol and the overlay signal was also significantly weaker. We believe that the low pH
of 5.5 and enzymes within the endosomes trigger the release of PTX via breakdown of the
polymer and destabilization of the micelle.
In our experiments, we were not able to discern a clear mechanism of PTX transfer from
untargeted micelles to the cytosol; previous studies show that the uptake of hydrophobic
drugs like PTX from untargeted polymeric micelles occurs via a combination of different
processes(32-34): 1) PTX could be transferred from the micelles to the plasma membrane
via small molecule diffusion, 2) PTX could be released in the extracellular environment for
uptake by cells via pinocytosis and 3) PTX could be internalized together with the polymeric
micelle via nonspecific endocytosis, with subsequent release from cellular compartments.
The resulting delivery of PTX is therefore less controlled and less efficient, leading to
reduced therapeutic efficiencies in vivo.
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In vivo anti-tumor efficacy with KB xenografts
We evaluated the efficacy of PTX loaded LDP micelles against a KB xenograft (s.c.
injection on right flank, day 0) model in nude mice. When the induced tumors were
palpable, mice were randomly divided into groups of 7 for treatment (Figure 5). Compared
to the controls (v and vi), all treatments showed varying degrees of efficacy in slowing the
growth of the xenograft. After four doses of therapy, the mean±SEM (n=7) tumor sizes were
738±100 mm3, 225±45 mm3, 1230±250 mm3, 390±118 mm3, 2170±213 mm3 and
2230±159 mm3 on day 22 for treatments i, ii, iii, iv, v, and vi respectively. As seen in Figure
5A, significantly smaller tumors on PTX treatment groups were observed in comparison to
control groups by ANOVA at the 95% confidence interval. Importantly, the data shows that
the folate clustered micelle treatment (PTX dosage = 2.5 mg/kg) is as effective as a higher
dose of free PTX (10 mg/kg), while free drug delivered at the same dose (2.5 mg/kg) had a
minimal effect in slowing down tumor growth (Figure 5B). This four fold increase in
therapeutic effect afforded by the targeted treatment is attributed the stronger retention of
targeted micelles in tumors, as observed with biodistribution. The folate-targeted treatment
had the best long-term efficacy, increasing survival time by approximately twice compared
to the controls; the median survival times of the different treatment groups were 39, 48, 34,
46, 23 and 25 days for treatments i, ii, iii, iv, v, and vi respectively and the percentage mean
survival time of the treated against the control (vi) (%T/C) was 158%, 201%, 138%, 186%
and 100% for treatments i, ii, iii, iv, and v respectively. A mantel-cox statistical test between
the survival curves show that they are significantly different with a P value of 0.001.
Untargeted micelles are not expected to be internalized by cells in significant quantity
following accumulation in the tumor interstitial space; therefore, while entrapped PTX in
folate targeted micelles are actively internalized by tumor cells with subsequent intracellular
release of drug (Figure 4), the mechanism of PTX delivery for untargeted LDP micelles
could be a combination of the different processes(33) for non-specific, random and less
efficient uptake of PTX. Furthermore, biodistribution data (Figure 3) of targeted vs
untargeted micelles at long time points also shows faster clearance of non-targeted LDP
micelles from tumors. Histological analysis (Figure 5C) with TdT mediated dUTP nick end
labeling (TUNEL) of tumors revealed the presence of apoptotic cells far away from the
blood vessels. This indicates that upon arrival in the tumor, the micelles are also able to
diffuse within the interstitial regions so that the delivery of PTX is not limited to tumor cells
found immediately around the blood vessels, which would limit the efficacy of treatment.
The body weights of the mice were monitored throughout the experiment as an indication of
adverse effects of the drug. None of the mice were euthanized as a result of excessive weight
loss (>15%). While all mice registered positive weight gain, those that were receiving
treatments of free PTX showed smaller weight increments over the period of treatment,
suggesting a low level of toxicity with the treatment (Supplemental Figure 3).
Discussion
The ability to achieve optimal ligand recognition and subsequently trigger receptor-mediated
processes for endocytosis is key to the concept of targeting drugs via specific interactions.
This is particularly important for cytotoxins such as cancer drugs; much larger and more
regular dosages are needed to achieve therapeutic benefit if only a small percentage of the
drug that reaches tumor sites are internalized. The high degree of colloidal stability of the
micelles greatly enhanced the blood circulation times and bioavailability of drug. As a
result, the measured circulation half-life of our encapsulated drug was significantly higher
than values reported in preclinical trials for block copolymers in the literature. For example,
Genexol, a poly(ethylene glycol)-block-poly(D,L-lactide) linear polymer carrying PTX was
found to have half-lives of less than 1 h(35). The importance of drug stability within carrier
systems during in vivo circulation has been given much attention lately(2,12,36). We show
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that PTX is remains within the LDP carrier for at least 2 h following systemic injection,
which is sufficient time to allow their distribution to tumors in significant quantity via
enhanced permeation and retention(37) (EPR). Recent investigations(12,36,38) of more
traditional linear block copolymers show that much of the encapsulated drug can be lost
within the first 5 min after intravenous injection, leading to a different distribution profile of
the drug and micelle; these observations are in contrast to our findings for the linear-
dendritic systems described here. The longer stability observed can be attributed to the low
micelle CMC for LDP micelles, making the system more resistant to dilution effects and
destabilization by in vivo conditions; however, our data also suggests a gradual loss of PTX
from the micelles at longer time points via slow leakage of drug from the interior of the
micelle, and future design of the system may be applied to further address this issue.
By presentation of the folate ligand in clusters, targeting of the micelles to FR expressing
cells is increased dramatically, leading to a clear observation of tumor targeting with
biodistribution data indicating increased accumulation over a 5 day period. Although there
have been conflicting reports(39-41) on the impact of ligand targeting on tumor
biodistribution, our data supports the notion that ligands can play a meaningful role in tumor
targeting after the LDP micelles are distributed to tumor sites via EPR(40,42). Both targeted
and untargeted micelles accumulated similarly (~5%ID/g) via EPR in tumors after systemic
administration (time points < 3 h); however, only the targeted micelles were able to
efficiently enter tumor cells from the extracellular space through FR mediated uptake,
leading to a higher level of retention within the tumor. Contrary to our observations,
examinations of other targeted delivery systems(39-41) employing folate or a different
ligand presented in a non-clustered manner on the nanoparticle surface showed that ligand
targeting did not improve the biodistribution of the carrier in tumors beyond the EPR effect
of non-targeted systems. We postulate that optimal cluster presentation of folate on the
targeted LDP micelles enhances their avidity and increases their residence times on FR
expressing KB cells in the tumor; this effect translates to a greater degree of uptake and the
high level of tumor localization observed over a longer period of time is a reflection of this.
This greater targeting effect also led to potency of therapy and a low PTX dose of 2.5 mg/kg
given once in 4-5 days is sufficient to achieve significant anti-tumor treatment. For
achieving a relatively similar effect, this dosage regimen is much lighter in comparison to
other studies involving folate-mediated therapy(43-45). These studies demonstrate the use of
ligand clustered linear-dendritic “patchy” micelles as an effective drug delivery system and
its potential for use as a platform delivery vehicle for optimization of targeted therapy
against cancers expressing other receptor targets of interest.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
(A) Chemical structure of the linear dendritic polymer (LDP) made from biocompatible and
degradable elements (Xn = 12-15). Blue = Hydrophilic, Red = Hydrophobic. Schematic
showing the preparation of paclitaxel (PTX) encapsulated LDP micelles that do not present
folate or present folate clusters for enhanced cell targeting. (B) Micellar morphology of
PTX-untargeted LDP nanoparticles by height-mode AFM measurement. Micelle diameters
are 80±6 nm with a surface charge of -25±3 mV by dynamic light scattering and zeta
potential measurements. (C) In vitro release of PTX at 37°C in fetal calf serum at pH 7.4 and
5.5 shows that PTX will be stable in circulation but acidic endosomes will trigger release of
PTX. (Data in mean ± SEM)
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Figure 2.
Blood circulation profiles of targeted micelle (A) and PTX (B) in encapsulated and free
form for non-tumored BALB/c mice (mean±SEM, n=3-5). The two-phase log-linear
decrease in concentration is fitted to a two compartment pharmacokinetic model: C = Ae-αt
+ Be-βt. (C) Definitions: α: elimination half-life; β: distribution half-life; A: rate of loss from
blood to peripheral tissue; B: rate of loss from peripheral tissue to blood; C: concentration in
blood after injection; AUC, area under the curves from zero to infinity. Data is reported as
percentage injected dose/gram of blood (%ID/g) for micelle and microgram of PTX/gram of
blood (μg/g) for PTX.
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Figure 3.
Biodistribution of systemically administered LDP micelles, untargeted (A) and folate-
targeted (B) in nude mice bearing KB xenografts (mean±SEM, n=3-5) over a 5 day period,
measured in units of percentage injected dose/gram tissue (%ID/g). Slower cumulative
clearance of the targeted micelle can be attributed to the sustained accumulation in KB
tumors as well as the presence of FRs in the kidneys. (C) Targeted micelle imaged in the
right flank KB tumor of nude mice 48 h post injection shows excellent tumor extravasation.
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Figure 4.
Confocal microscopy analysis (60X) of the delivery of PTX (AF488, green) encapsulated in
folate LDP micelles (AF647, red) in KB cells. Cell nuclei are stained with Hoechst (blue).
Scale bar = 10 μm. PTX-folate micelle conjugates are internalized as a whole via FRs and
can stay within endosomes for up to 5 h. By 10 h, the low pH of 5.5 and enzymes within the
endosome and lysosomes trigger the release of PTX via destabilization of the micelle and
breakdown of the polymer, which then diffuses out into the cytosol to cause apoptosis.
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Figure 5.
Anti-tumor study in nude mice (n=7) bearing KB xenografts (s.c. injection on right flank,
day 0). Treatment began on day 4, when tumors were palpable and mice were given a single
dose intravenous injection (tail vein) on day 4, 8, 12 and 16 of the following: (i) untargeted
LDP micelles (100 mg/kg) delivering 2.5 mg/kg PX, (ii) folate targeted LDP micelles (100
mg/kg) delivering 2.5 mg/kg PTX, (iii) 2.5 mg/kg free PTX in 1:1 Cremophor:EtOH (1 %v/
v) as excipient, (iv) 10 mg/kg free PTX in 1:1 Cremophor:EtOH (1 %v/v) as excipient (v)
LDP micelles (100 mg/kg) without PTX and (vi) Saline. Mice were evaluated over a period
of 60 days. A) Tumor volume over the first 22 days of treatment. Data is given in mean
±SEM for n=7. Kaplan-Meier plot of survival times for mice receiving treatments also show
that the targeted therapy had the best long-term efficacy. B) Representative mouse at day 20
(2 days after last treatment) for folate targeted and free PTX treatments at the same dosage
level of 2.5 mg/kg. C) Representative histological sections of tumors extracted from mice
receiving targeted (ii) and control (vi) treatment. Cell nuclei = blue (Hoechst); Blood vessels
= green (CD31-FITC); Apoptotic cells = red (TUNEL, A647). Presence of apoptotic cells
far away from blood vessels suggests that micelles were able to penetrate tumor tissue
effectively. Scale bar = 250 μm. (Data in mean ± SEM)
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